On October 19, 2026 Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, reported that updated clinical data for zolucatetide in patients with desmoid tumors will be presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026, taking place October 23–27, 2026, in Madrid, Spain.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The oral presentation will report data from a June 22, 2026, data cutoff, including data from both the dose escalation and dose optimization portions of the ongoing Phase 1/2 trial. Dose optimization in the desmoid tumor-specific cohort is designed to inform selection of the dose and schedule to be carried forward into the planned registrational Phase 3 trial of zolucatetide in patients with desmoid tumors.
Zolucatetide has received both Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of desmoid tumors.
Presentation Details
Title: A phase 1/2 trial of zolucatetide, a first-in-class direct β-catenin:TCF inhibitor: updated safety and efficacy in patients with desmoid tumors
Abstract Number: 3715O
Presenter: Mrinal Gounder, M.D., Memorial Sloan Kettering Cancer Center
Session: Proffered Paper Session: Sarcoma
Date & Time: Saturday, October 24, 2026, 14:45–16:15 CEST (8:45–10:15 a.m. EDT)
Location: Malaga Auditorium – Hall 3, IFEMA Madrid, Madrid, Spain
Investor Webcast
Parabilis will host an investor webcast on Saturday, October 24, 2026, at 18:00 CEST (12:00 p.m. EDT) to discuss the updated zolucatetide data that will be presented at ESMO (Free ESMO Whitepaper) Congress 2026. The webcast will be available on the Investors section of the Parabilis website at View Source A replay will be available following the event.
About Desmoid Tumors
Desmoid tumors are locally invasive soft-tissue tumors that arise in connective tissues and can be aggressive and recurrent, often causing chronic pain, limited mobility, disfigurement and organ dysfunction. An estimated 30,000 people in the U.S. alone are living with desmoid tumors, including approximately 11,000 who are actively managed, with significant unmet need globally as well. Desmoid tumors typically present in young adults, with many patients requiring prolonged or intermittent treatment. Wnt/β-catenin pathway-activating mutations are the causal driver of desmoid tumors, yet no approved therapies directly target this underlying biology of the disease.
About Zolucatetide
Zolucatetide is an investigational first-in-class and first-and-only direct inhibitor of the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors, a genetically validated driver of numerous cancers and other serious diseases that has long been considered undruggable. Developed using Parabilis’ Helicon peptide platform, zolucatetide is designed to prevent the activation of disease-driving genes by directly targeting β-catenin:TCF, a key downstream node in the Wnt/β-catenin pathway. This approach has the potential to address aberrant Wnt/β-catenin signaling regardless of the upstream APC or β-catenin mutations driving pathway activation, potentially overcoming a key limitation of approaches targeting earlier steps in the pathway.
Zolucatetide is currently being evaluated in an ongoing Phase 1/2 clinical trial (NCT05919264) across a range of indications, including desmoid tumors, familial adenomatous polyposis (FAP), adamantinomatous craniopharyngioma (ACP), hepatocellular carcinoma (HCC) and additional Wnt-driven tumor types.
(Press release, Parabilis Medicines, OCT 19, 2026, View Source [SID1234673599])